BRCA1 and breast carcinoma: Nonetheless, similar data have been found in a phase II trial that evaluated talazoparib in patients with advanced HER2-negative breast cancer or other solid tumors with a germline or somatic alteration in HRR-related genes other than BRCA1/2.